Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2018-02-22, 14:25:50 | version 1.38.0
Dental Tribune Middle East & Africa Edition | 3/2016 news 37 Trusted market leader since 1967. Representing some International major companies such as: ABU DHABI SHOWROOM TEL. (02) 673 0790 FAX. (02) 673 1995 SHARJAH INDUSTRIAL AREA OFFICE TEL. (06) 535 5575 FAX. (06) 5350839 SHARJAH BUHAIRAH SHOWROOM TEL. (06) 555 3922 FAX. (06) 555 1300 DrMicheleBarbour(Photograph:BhageshSachania,UniversityofBristol) Bristolresearchers receivefundingfor super-chlorhexidine ByDTI BRISTOL, UK: A University of Bristol spin-off has been awarded almost £1 million to bring a new technology to the market that could help to fight infections in the mouth and body. An enhanced form of chlorhexidine, the substance, named Pertinax, is said to offer improved properties compared with those of the original substance. Overall, Pertinax Pharma has re- ceived around £900,000 from southern England technology inves- tor Mercia Fund Management, Inno- vateUK(throughitsAidforStart-Ups scheme)andanunnamedprivatein- vestor. The company’s founder and chief scientific officer, Dr Michele Barbour, who is also a senior lecturer in biomaterials at the university’s School of Oral and Dental Sciences, said that the company will focus on the development of applications in dentistry first, where the technology alreadyhasrelevancetoanumberof areas. Further uses in medicine will followintime. “We’re very excited about Pertinax’s potential,”shesaid. A proven antimicrobial agent, chlo- rhexidine has been used in a wide range of products and treatment processes to prevent and treat bac- terial infections. Since it is a new formulation of the substance, Perti- nax is reported to possess the same antibacterial properties, but without some of the shortcomings of the original formulation, such as short efficacy time. Possible future ap- plications are its use in cements to reduce the failure rates of dental fill- ings,forexample. “With a strong management team and innovative product, Pertinax Pharma has the potential to take its product from dental tool to a must- have anti-infective across a wide range of industries, from veterinary care, to cosmetics and even home appliances,” Investment Manager at Mercia Fund Management Dr BrijeshRoycommented. Mercia Fund Management recently provided funding for another oral health care-related project by the UniversityofManchester. “We’reveryexcitedabout Pertinax’spotential.” TEL. (02) 6730790 FAX. (02) 6731995 TEL. (06) 5355575 TEL. (06) 5553922 FAX. (06) 5551300